Recent News

• 05.09.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 05.09.2025 - 8-K - Current report
• 05.06.2025 - Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
• 04.28.2025 - Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
• 04.28.2025 - Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
• 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities

Recent Filings

• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities